Evidence map›Paper›PMID 39715263›Full record

ArticlePLoS computational biology2024

Predicting the infecting dengue serotype from antibody titre data using machine learning.

Bethan Cracknell Daniels, Darunee Buddhari, Taweewun Hunsawong, Sopon Iamsirithaworn, Aaron R Farmer, Derek A T Cummings, Kathryn B Anderson, Ilaria Dorigatti

Abstract read
In one paragraph

Article in PLoS computational biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Bethan Cracknell DanielsMRC Centre for Global Infectious Disease Analysis and the Abdul Latif Jameel Institute for Disease and Emergency Analytics, School of Public Health, Imperial College London, London, United Kingdom.ORCID 0000-0002-3707-5706
Darunee BuddhariDepartment of Virology, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand.
Taweewun HunsawongDepartment of Virology, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand.
Sopon IamsirithawornDepartment of Disease Control, Ministry of Public Health, Thailand.
Aaron R FarmerDepartment of Virology, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand.
Derek A T CummingsDepartment of Biology and Emerging Pathogens Institute, University of Florida, Gainesville, Florida, United States of America.
Kathryn B AndersonDepartment of Microbiology, SUNY Upstate Medical University, Syracuse, New York, United States of America.
Ilaria DorigattiMRC Centre for Global Infectious Disease Analysis and the Abdul Latif Jameel Institute for Disease and Emergency Analytics, School of Public Health, Imperial College London, London, United Kingdom.ORCID 0000-0001-9959-0706

Funding

Defining correlates of protection from dengue illness in a long-term cohort study of multigenerational house-holds in ThailandR01AI175941 · NIAID · UPSTATE MEDICAL UNIVERSITY · PI Kathryn B Anderson · 2023 to 2026
$2.7M
Identification of serological markers of protection and risk for dengue vaccines and natural infectionR01AI175495 · NIAID · UNIVERSITY OF FLORIDA · PI Derek A Cummings · 2023 to 2026
$2.7M
NIAID NIH HHS R01 AI175495NIAID NIH HHS R01 AI175941NIH HHS P01 A1034533Wellcome Trust
6 · The paper itself

Abstract

The development of a safe and efficacious vaccine that provides immunity against all four dengue virus serotypes is a priority, and a significant challenge for vaccine development has been defining and measuring serotype-specific outcomes and correlates of protection. The plaque reduction neutralisation test (PRNT) is the gold standard assay for measuring serotype-specific antibodies, but this test cannot differentiate homotypic and heterotypic antibodies and characterising the infection history is challenging. To address this, we present an analysis of pre- and post-infection antibody titres measured using the PRNT, collected from a prospective cohort of Thai children. We applied four machine learning classifiers and multinomial logistic regression to the titre data to predict the infecting serotype. The models were validated against the true infecting serotype, identified using RT-PCR. Model performance was calculated using 100 bootstrap samples of the train and out-of-sample test sets. Our analysis showed that, on average, the greatest change in titre was against the infecting serotype. However, in 53.4% (109/204) of the subjects, the highest titre change did not correspond to the infecting serotype, including in 34.3% (11/35) of dengue-naïve individuals (although 8/11 of these seronegative individuals were seropositive to Japanese encephalitis virus prior to their infection). The highest post-infection titres of seropositive cases were more likely to match the serotype of the highest pre-infection titre than the infecting serotype, consistent with antigenic seniority or cross-reactive boosting of pre-infection titres. Despite these challenges, the best performing machine learning algorithm achieved 76.3% (95% CI 57.9-89.5%) accuracy on the out-of-sample test set in predicting the infecting serotype from PRNT data. Incorporating additional spatiotemporal data improved accuracy to 80.6% (95% CI 63.2-94.7%), while using only post-infection titres as predictor variables yielded an accuracy of 71.7% (95% CI 57.9-84.2%). These results show that machine learning classifiers can be used to overcome challenges in interpreting PRNT titres, making them useful tools in investigating dengue immune dynamics, infection history and identifying serotype-specific correlates of protection, which in turn can support the evaluation of clinical trial endpoints and vaccine development.

Indexed as

Antibodies, ViralDengueDengue VirusMachine LearningSerogroupChildChild, PreschoolComputational BiologyHumansMaleProspective StudiesThailandAntibodies, Viral

Identifiers

PMID39715263
PMCPMC11706371

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.